Fudan-Zhangjiang approves charter changes, expands board with new director

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that its extraordinary general meeting (EGM) on November 26, 2025, approved several key resolutions. These included a change in use of A share initial public offering proceeds and amendments to the Articles of Association and rules of procedure for both the general meeting and the board of directors. All resolutions were duly passed by poll.

Following these approvals, the company's supervisory committee has been dissolved, with its powers and functions now transferred to the audit committee of the board. Consequently, Huang Jian, Zhou Aiguo, and Qu Yanan will no longer serve as supervisors. Concurrently, Qu Yanan has been elected as an employee director to the board, increasing the total number of board members from seven to eight.

As of this announcement, Qu holds 39,000 A shares, representing approximately 0.004% of the total issued share capital. The board now comprises executive, non-executive, independent non-executive, and an employee director, with Qu serving as the employee director.